IPF Survival Better With Novel Drug?

Author: Crystal Phend
Date Published: May-2014
Source: Medpage Today

SAN DIEGO -- The novel antifibrotic drug pirfenidone (Esbriet) slowed progression of idiopathic pulmonary fibrosis (IPF) in the ASCEND trial, which also turned up a survival benefit when pooled with prior pivotal trials. The oral agent nearly halved the incidence of a decline in forced vital capacity (FVC) by 10 percentage points or death at 1 year compared with placebo (16.5% versus 31.8%, P<0.001), Talmadge E. King Jr., MD, of the University of California San Francisco, and colleagues found. While the trial didn't show an improvement in overall or disease-specific survival, a pooled analysis with the two prior pivotal trials (CAPACITY trials) did favor pirfenidone on both counts, they reported at the American Thoracic Society meeting and simultaneously online in the New England Journal of Medicine.